$HUM

Humana (HUM) Shares Surge 13% on CMS Four-Star Medicare Advantag

Humana Inc (HUM) shares rose 13% after CMS upgraded its Medicare Advantage contract to a four-star rating, restoring eligibility for quality bonus payments affecting 2.4 million members. The company's GF Value™ suggests it is 1.5% overvalued at $387.12, with a GF Score™ of 83/100. Insiders have been net buyers over the past year.

Original reporting
Published Oct 9, 2026, 10:56 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 9, 2026, 12:02 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMarket movers
Primary signal
$HUM
Bullish
high confidence
Mentioned
$HUM
Relevance
8/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$HUMBullishMed
01

Why it matters

The CMS four‑star rating reinstates quality bonus eligibility for 2.4 million members, enhancing margin recovery and prompting a sharp share price increase.

02

Market read

The rating upgrade is a material catalyst for Humana, driving a 13% price jump and likely influencing peer valuations in the health‑insurance sector.

03

What to watch

Potential regulatory scrutiny of CMS rating methodology and the sustainability of margin improvements beyond the bonus period.

Relevance 8/10Novelty 7/10Timing: today

Background

Humana (NYSE:HUM) provides Medicare Advantage, Medicaid, and pharmacy benefit management services, with a market cap of ~$46 billion.

Company-level read

Ticker impact

$HUMBullishHigh confidence
Context

CMS upgraded Humana's primary Medicare Advantage contract to a four‑star rating, restoring eligibility for quality bonus payments and triggering a 13% stock surge.

Expected impact

potential near‑term pressure as the rally may pause once the upgrade is fully priced in

Evidence & confidence

The rating directly improves cash flow prospects for 2.4 million members, but the 13% move suggests the market may have over‑reacted, leading to short‑term consolidation.

Market effects

Boosts sentiment for the broader Medicare Advantage and health‑insurance sector as quality‑bonus eligibility is reaffirmed.

Positive impact on U.S. health‑care stocks, especially peers with similar CMS contracts.

Limited to U.S. markets; no direct global effect.

Counterpoint

The rapid 13% rally may be overstated; investors should watch for profit‑taking and assess whether the bonus payments materially exceed expectations.

Key entities

  • Centers for Medicare & Medicaid Services

    Federal agency that rates Medicare Advantage contracts.

  • Humana Inc.

    U.S. health‑insurance provider.

Related articles

$HUMHighAI 8/10

Humana Stock Surges 14% as Medicare Ratings Hit CVS Health

Humana's stock rose 14% after its Medicare Advantage plans saw a significant improvement in quality ratings, with 95% of members in 4-star or higher plans for 2027. This could bring $3.6B in additional revenue. CVS Health's Aetna saw a decline in ratings, with 69% of members in 4-star or higher plans, down from 81%.

$HUMHighAI 8/10

Humana surges after emerging as top beneficiary of 2027 Medicare star ratings

Humana's shares rose 15% premarket after analysts identified it as the top beneficiary of 2027 Medicare star ratings. 95% of its Medicare Advantage members will be in plans rated 4 stars or higher, up from 20% in 2026. Analysts expected 60-70%. Higher ratings lead to government bonus payments and boost enrollment. Humana's ratings outperform larger rivals like UnitedHealth and CVS Health, according to J.P. Morgan.

$HUMMed

Humana exceeds Top Quartile 2027 MA Stars; affirms at least $9.00 FY2026 adjusted EPS

Humana reported exceeding its Top Quartile goal for 2027 Medicare Advantage Star Ratings, with Stars revenue PMPM 10% above peer median. The company reaffirmed its FY2026 adjusted EPS guidance of at least $9.00. Humana plans to treat some 2028 outperformance as a one-time benefit for investments and shareholder return. A virtual investor update is scheduled for December 10, 2026.